Karyopharm Therapeutics Inc. (KPTIQ) company profile

Karyopharm Therapeutics Inc. is a pharmaceutical company that focuses on the discovery, development, and commercialization of treatments such as Xpovio. Operating within the healthcare sector, the business develops product candidates and enters into commercial collaborations and licensing agreements with partner firms, including Menarini and Antengene Therapeutics. Through these arrangements, the company provides products and licenses its pharmaceutical assets to partners and customers across the industry.

The company maintains operational activities in the United States and works with international licensing partners. Its principal executive offices and headquarters are located at 85 Wells Avenue, 2nd Floor, in Newton, Massachusetts. In addition, the organization leases dedicated office and research space to conduct its operations and support its business initiatives.

Summary of the business section of Karyopharm Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Per Share Total Public offering price $16.00 $108,800,000 Underwriting discount(1) $1.12 $7,616,000 Proceeds, before expenses, to us $14.88 $101,184,000 (1) We refer you to "Underwriting" on page 165 for additional information regarding total underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of February 5, 2026, we had 228 employees, all of whom were full-time employees.”